news
First patient receives new engineered mRNA epigenetic
OTX-2002, a programmable epigenetic medicine is the first mRNA therapy to target MYC dysregulation and could treat hepatocellular carcinoma.
List view / Grid view
R&D
whitepaper
iPDF: Lab efficiency calculator
This easy-to-use iPDF tool helps you estimates how much time and money you throw away thanks to inefficient lab inventory practices.
news
Astellas invests $50 million in Taysha Gene Therapies
Taysha will license AAV gene therapy candidates TSHA-102 for Rett syndrome and TSHA-120 for giant axonal neuropathy to Astellas.
news
NICE recommends first oral GnRH antagonist for uterine fibroids
Ryeqo, a one-per-day oral drug for adults with moderate-to-severe symptoms of uterine fibroids has been given the green light by NICE.
news
University of Oklahoma to open bioprocessing training facility
The centre will help prepare engineers and advance research in this emerging industry, according to Gallogly College of Engineering’s Associate Dean for Research.
news
ITM licenses targeted radionuclide therapy candidate
The targeted radionuclide therapy for glioblastoma is administered into a tumour cavity via a reservoir post-surgery and standard post-operative therapy.
news
AstraZeneca dual immunotherapy approved for US liver cancer patients
The FDA has approved Imfinzi™ combined with Imjudo for adults with unresectable liver cancer, based on a lower risk of death compared to only sorafenib.
news
UK research consortium given £2 million to control monkeypox
£2 million will help fund a UK team of scientific experts to research monkeypox, uncover novel treatments and curb the spread of the virus.
article
Make confident operational decisions by understanding your microflora
Are you leveraging all the information from your QC data? A secure, compliant and powerful data management tool is critical for maintaining a state of control.
news
Three-dose vaccine prevents HIV patients getting hepatitis B
Clinical trial results suggest adult HIV patients can be protected against hepatitis B with a three-dose vaccine series.
news
Gilead and MacroGenics to develop bispecific cancer antibodies
A collaboration agreement between Gilead and biopharma company MacroGenics aims to develop MGD024, a bispecific antibody for treatment of blood cancers.
news
Shingles vaccine offers a decade of protection in older adults
Shingrix can effectively vaccinate adults over 50 years old against shingles for at least 10 years, new data shows.
news
First patient receives novel, potentially cancer-stopping pill
City of Hope has developed AOH1996, a promising cancer medicine, for people with reoccurring solid tumours.
news
Lilly will acquire Akouos to accelerate hearing loss therapies
Eli Lilly and Company’s $610 million acquisition of Akouos will fast-track gene therapies that restore, improve and preserve hearing for patients worldwide.
news
$38 million will fund rare disease research over four-year period
Research for rare diseases including ALS will be supported over the next four years by $38 million in FDA funding.
